Obara Wataru, Konda Ryuichiro, Akasaka Shuntaro, Nakamura Shinichi, Sugawara Akira, Fujioka Tomoaki
Department of Urology, Central Clinical Laboratory, Iwate Medical University School of Medicine, Morioka, Japan.
J Urol. 2007 Oct;178(4 Pt 1):1497-503. doi: 10.1016/j.juro.2007.05.119. Epub 2007 Aug 16.
The active form of vitamin D3, that is 1alpha,25-dihydroxyvitamin D3, binds with vitamin D receptor, which forms a complex with retinoid X receptors alpha, beta and gamma to manifest antitumor effects. We examined the expression of vitamin D receptor and retinoid X receptors in renal cell carcinoma and elucidated the prognostic significance of these receptors.
We performed immunohistochemical examination of vitamin D receptor, and retinoid X receptors alpha, beta and gamma in nephrectomized specimens of 68 patients with renal cell carcinoma. We analyzed the correlation between the expression of these receptors and clinicopathological parameters or patient survival. Mean followup was 68.2 months.
No significant correlation was found between the expression of vitamin D receptor, retinoid X receptor alpha or beta and clinicopathological parameters. In contrast, retinoid X receptor gamma expression correlated significantly with tumor stage (p = 0.009) and distant metastasis (p = 0.005). The 5-year cancer specific survival rate was higher in patients with retinoid X receptor gamma positive renal cell carcinoma than those with retinoid X receptor gamma negative renal cell carcinoma (79.3% vs 40.0%, p <0.05). Cox regression analysis revealed that retinoid X receptor gamma expression, tumor status and lymph node status were significant independent prognostic factors in patients with renal cell carcinoma (p <0.05). A significant correlation was observed between the expression of retinoid X receptor gamma and tumor stage, distant metastasis or the 5-year cancer specific survival rate. Furthermore, retinoid X receptor gamma expression was an independent prognostic factor in patients with renal cell carcinoma.
Our observations suggest that alterations of vitamin D receptor and retinoid X receptor expression may be involved in renal carcinogenesis and retinoid X receptor gamma expression may be a useful prognostic marker in patients with renal cell carcinoma.
维生素D3的活性形式,即1α,25 - 二羟基维生素D3,与维生素D受体结合,该受体与视黄酸X受体α、β和γ形成复合物以发挥抗肿瘤作用。我们检测了肾细胞癌中维生素D受体和视黄酸X受体的表达,并阐明了这些受体的预后意义。
我们对68例肾细胞癌患者的肾切除标本进行了维生素D受体以及视黄酸X受体α、β和γ的免疫组化检测。我们分析了这些受体的表达与临床病理参数或患者生存率之间的相关性。平均随访时间为68.2个月。
维生素D受体、视黄酸X受体α或β的表达与临床病理参数之间未发现显著相关性。相比之下,视黄酸X受体γ的表达与肿瘤分期(p = 0.009)和远处转移(p = 0.005)显著相关。视黄酸X受体γ阳性的肾细胞癌患者的5年癌症特异性生存率高于视黄酸X受体γ阴性的肾细胞癌患者(79.3%对40.0%,p <0.05)。Cox回归分析显示,视黄酸X受体γ表达、肿瘤状态和淋巴结状态是肾细胞癌患者重要的独立预后因素(p <0.05)。视黄酸X受体γ的表达与肿瘤分期、远处转移或5年癌症特异性生存率之间存在显著相关性。此外,视黄酸X受体γ表达是肾细胞癌患者的独立预后因素。
我们的观察结果表明,维生素D受体和视黄酸X受体表达的改变可能参与了肾癌的发生,视黄酸X受体γ表达可能是肾细胞癌患者有用的预后标志物。